Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
Conditions
Interventions
KVD900
Placebo
Locations
25
United States
KalVista Investigative Site
Scottsdale, Arizona, United States
KalVista Investigative Site
Centennial, Colorado, United States
KalVista Investigative Site
Chevy Chase, Maryland, United States
KalVista Investigative Site
Cincinnati, Ohio, United States
KalVista Investigative Site
Dallas, Texas, United States
KalVista Investigative Site
Spokane, Washington, United States
Start Date
July 2, 2019
Primary Completion Date
December 8, 2020
Completion Date
December 8, 2020
Last Updated
May 2, 2025
NCT07298447
NCT06960213
NCT06842823
NCT06573723
NCT06634420
NCT05392114
Lead Sponsor
KalVista Pharmaceuticals, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions